Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

NCT05399329 · clinicaltrials.gov ↗

COMPLETED

Status

693

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Endocrine therapy

Sponsor

Pfizer